Literature DB >> 12852751

Unique high-affinity synthetic mu-opioid receptor agonists with central- and systemic-mediated analgesia.

Yoshio Okada1, Yuko Tsuda, Yoshio Fujita, Toshio Yokoi, Yusuke Sasaki, Akihiro Ambo, Ryoji Konishi, Mitsuhiro Nagata, Severo Salvadori, Yunden Jinsmaa, Sharon D Bryant, Lawrence H Lazarus.   

Abstract

Unique opioid mimetic substances containing identical N-terminal aromatic residues separated by an unbranched alkyl chain containing two to eight methylene groups were developed. Regardless of the length of interposing alkyl chain, the bis-Tyr and bis-Phe compounds were inactive; however, replacement by a single Dmt (2',6'-dimethyl-L-tyrosine) residue enhanced activity by orders of magnitude. Moreover, the bis-Dmt compounds were another 10-fold more potent with an optimum intra-aromatic ring distance of about four to six methylene units. 1,4-Bis(Dmt-NH)butane (7) had high mu-opioid receptor affinity (K(i) = 0.041 nM) and functional mu-opioid agonist bioactivity (IC(50) = 5.3 nM) with in vivo central (intracerebroventricular) and systemic (subcutaneous) analgesia in mice (1.5- to 2.5-fold greater than and 10-12% relative to morphine, respectively); these activities were reversed by naloxone to the same degree. It appears that the bis-Dmt compounds indiscriminately act as both message and address domains.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12852751     DOI: 10.1021/jm020459z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Synthesis of 3,6-bis[H-Tyr/H-Dmt-NH(CH2)m,n]-2(1H)pyrazinone derivatives: function of alkyl chain length on opioid activity.

Authors:  Kimitaka Shiotani; Tingyou Li; Anna Miyazaki; Yuko Tsuda; Sharon D Bryant; Akihiro Ambo; Yusuke Sasaki; Lawrence H Lazarus; Yoshio Okada
Journal:  Bioorg Med Chem Lett       Date:  2006-09-01       Impact factor: 2.823

2.  A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic.

Authors:  Severo Salvadori; Claudio Trapella; Stella Fiorini; Lucia Negri; Roberta Lattanzi; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus; Gianfranco Balboni
Journal:  Bioorg Med Chem       Date:  2007-08-29       Impact factor: 3.641

3.  Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability.

Authors:  Sean P Henry; Thomas J Fernandez; Jessica P Anand; Nicholas W Griggs; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2019-04-12       Impact factor: 7.446

4.  Design and synthesis of opioidmimetics containing 2',6'-dimethyl-L-tyrosine and a pyrazinone-ring platform.

Authors:  Kimitaka Shiotani; Tingyou Li; Anna Miyazaki; Yuko Tsuda; Toshio Yokoi; Akihiro Ambo; Yusuke Sasaki; Sharon D Bryant; Lawrence H Lazarus; Yoshio Okada
Journal:  Bioorg Med Chem Lett       Date:  2007-08-28       Impact factor: 2.823

5.  Inhibition of the development of morphine tolerance by a potent dual mu-delta-opioid antagonist, H-Dmt-Tic-Lys-NH-CH2-Ph.

Authors:  Yunden Jinsmaa; Ewa D Marczak; Gianfranco Balboni; Severo Salvadori; Lawrence H Lazarus
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

6.  Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides.

Authors:  Yasuko Koda; Mark Del Borgo; Susanne T Wessling; Lawrence H Lazarus; Yoshio Okada; Istvan Toth; Joanne T Blanchfield
Journal:  Bioorg Med Chem       Date:  2008-04-15       Impact factor: 3.641

7.  Conformationally constrained opioid ligands: the Dmt-Aba and Dmt-Aia versus Dmt-Tic scaffold.

Authors:  Steven Ballet; Debby Feytens; Rien De Wachter; Magali De Vlaeminck; Ewa D Marczak; Severo Salvadori; Chris de Graaf; Didier Rognan; Lucia Negri; Roberta Lattanzi; Lawrence H Lazarus; Dirk Tourwé; Gianfranco Balboni
Journal:  Bioorg Med Chem Lett       Date:  2008-11-19       Impact factor: 2.823

Review 8.  Peptidomimetics and Their Applications for Opioid Peptide Drug Discovery.

Authors:  Yeon Sun Lee
Journal:  Biomolecules       Date:  2022-09-05

Review 9.  Developmental potential for endomorphin opioidmimetic drugs.

Authors:  Yoshio Okada; Yuko Tsuda; Severo Salvadori; Lawrence H Lazarus
Journal:  Int J Med Chem       Date:  2012-06-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.